GridAI Technologies Corp. SEC filings GRDX

GridAI Technologies Corp. has 767 filings in SEC EDGAR's recent list, going back to Apr 2, 2014. Its latest annual report, Form 10-K, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 21, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (officer or director change). The company's fiscal year ends on December 31.

GridAI Technologies Corp. SEC filings
Form Description Filed Period
10-K Annual report May 1, 2026 Dec 31, 2025
10-K/A Amended annual report Apr 9, 2025 Dec 31, 2024
10-K Annual report Apr 1, 2025 Dec 31, 2024
10-K Annual report Mar 29, 2024 Dec 31, 2023
ARS Annual report to shareholders May 15, 2023 Dec 31, 2022
10-K Annual report Mar 20, 2023 Dec 31, 2022
10-K/A Amended annual report May 10, 2022 Dec 31, 2021
10-K Annual report Mar 31, 2022 Dec 31, 2021
10-K Annual report Mar 31, 2021 Dec 31, 2020
10-K/A Amended annual report Apr 29, 2020 Dec 31, 2019
10-K Annual report Mar 30, 2020 Dec 31, 2019
10-K/A Amended annual report Apr 30, 2019 Dec 31, 2018
10-K Annual report Apr 1, 2019 Dec 31, 2018
10-K/A Amended annual report Apr 27, 2018 Dec 31, 2017
10-K Annual report Mar 16, 2018 Dec 31, 2017
10-K Annual report Mar 31, 2017 Dec 31, 2016

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Electric & Other Services Combined (SIC 4931)
Listed as
GRDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boca Raton, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1604191
Former names
Entero Therapeutics, Inc. (until Nov 19, 2025); First Wave BioPharma, Inc. (until May 16, 2024); AzurRx BioPharma, Inc. (until Sep 14, 2021); BioPharma d'Azur, Inc. (until Apr 2, 2014)

Other Electric & Other Services Combined companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.